Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (November 2018)
22 slides from Biotron's shareholder meeting presentation, Nov 20, 2018
Slide 1: Presentation to Annual General Meeting
Level 2, 666 Hunter Strreet Syd dney NSW 22000 For personal use only Tel: (61-2) 9300 3344 Fax: (61-2) 9221 66333 E-mail: p pnightingale@ @biotron.com m.au W Website: www w.biotron.comm.au 20 Novembber 2018 The Managger Compannies ASX Limitted 20 Bridge S Street SYDNEY NSW 20000 (22 ppages by em mai
Slide 2: Chairman's Address to the AGM
Level 2, 666 Hunter Strreet Syddney NSW 22000 For personal use only Tel: (61-2) 9300 3344 Fax: (61-2) 9221 66333 E E-mail: info@ @biotron.com m.au W Website: wwww.biotron.comm.au 20 Novembber 2018 w Shareholdeers My Fellow CH HAIRMAN’S ADDRES SS TO THE E AGM I am very ppleased to rreport on Biotron’
Slide 3: Chairman's Address (continued)
The Company is well funded, an unusual luxury for a small biotechnology player in the current market. We would like to think that while offering hope to the many millions of patients suffering from issues relating to the ailments on which we focus, maybe an end of tunnel light is being switched on f
Slide 4: For personal use only
For personal use only Slide title
Slide 5: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These state
Slide 6: Key Achievements 2018
Key Achievements 2018 For personal use only • Completed Phase 2 clinical trial of BIT225 and Combination Antiretroviral Therapy (cART) • Reported positive data in September 2018 • Presenting data from trial at HIV DART conference in late November 2018 • Raised $1.48 million (after costs) via rights
Slide 7: Biotron – New Approach to Anti-Viral Drug Development
Biotron – New Approach to Anti‐Viral Drug Development Biotron – New Approach to Anti‐Viral Drug Development For personal use only • Focused on the design and development of a new class of antiviral drugs targeting viral‐ encoded viroporin proteins • Viroporins are present in wide range of viruses: I
Slide 8: HIV-1 Eradication
HIV‐1 Eradication HIV‐1 Eradication For personal use only Current antiretroviral drugs to not cure HIV‐1 infection • HIV‐1 reservoirs set up early, leading to chronic, life‐long infection • Not sensitive to current anti‐HIV‐1 drugs • New mode of actions drugs are needed to eradicate or cure HIV‐1 in
Slide 9: BIT225 Targets HIV-1 Macrophage Reservoirs
BIT225 Targets HIV‐1 Macrophage Reservoirs For personal use only BIT225 targets and kills HIV‐1 in macrophage cells – these are a key reservoir of infection, even in people taking antiretroviral drugs Mario Stevenson Scientific American 299, 78 ‐ 83 (2008)
Slide 10: BIT225-009 Phase 2 HIV-1 Trial
BIT225‐009 Phase 2 HIV‐1 Trial For personal use only ‐ Double‐blind, placebo‐controlled, randomised, multi‐centre study Protocol ‐ 12 weeks, once daily, oral treatment with BIT225 or placebo in combination with antiretroviral treatment (ART) 36 HIV +ve, treatment‐naïve subjects commencing standard a
Slide 11: BIT225-009 Phase 2 HIV-1 Trial Outcomes
BIT225‐009 Phase 2 HIV‐1 Trial Outcomes For personal use only Pharmacokinetics (PK): ‐ Reports by third parties in progress. Data generally not reported, as details are considered trade secrets, other than required for regulatory filings ‐ Adds to a large body of data (over 200 subjects dosed in tri
Slide 12: BIT225-009 Phase 2 HIV-1 Trial Outcomes: Virological
BIT225‐009 Phase 2 HIV‐1 Trial Outcomes For personal use only Virological Outcomes (Measurement of virus levels in the blood) 1. Plasma viral loads • Standard way to measure effectiveness of anti‐HIV‐1 drugs • Routine diagnostic test run by pathology laboratories worldwide • Approved anti‐HIV‐1 drug
Slide 13: BIT225-009 Phase 2 HIV-1 Trial Outcomes: Immunological
BIT225‐009 Phase 2 HIV‐1 Trial Outcomes For personal use only Immunological Outcomes 1. Soluble CD163 • A macrophage immune activation marker found in the blood • High levels in untreated HIV+’s; levels are known to be lowered once on anti‐HIV‐1 drugs • BUT despite treatment with anti‐HIV‐1 drugs, s
Slide 14: BIT225-009 Phase 2 HIV-1 Trial Outcomes: Immunological
BIT225‐009 Phase 2 HIV‐1 Trial Outcomes For personal use only Immunological Outcomes 2. Other immunological markers • A range of other immunological markers have been assessed to determine impact of BIT225 • Statistically significant differences found between the BIT225 + ART cohort and the placebo
Slide 15: Trial Data Supports BIT225 Clearing Virus from Macrophage Reservoirs
Trial Data Supports BIT225 Clearing Virus from Macrophage Reservoirs For personal use only Infectious HIV‐1 Non‐infectious HIV‐1 • Cell culture studies showed that BIT225 targets A B formation of new virus in macrophage cells (Figs A and B), producing non‐infectious, dead virus • Immunological data
Slide 16: BIT225-009 Phase 2 HIV-1 Trial Outcomes: What They Mean
BIT225‐009 Phase 2 HIV‐1 Trial Outcomes For personal use only What do these results mean for BIT225 and Biotron’s HIV‐1 Program? ‐ The immunological data provide clear clinical evidence that BIT225 is having a unique effect in individuals infected with HIV‐1 ‐ This effect is not seen in individuals
Slide 17: Unlocking Value for Other Virus Targets
Unlocking Value for Other Virus Targets For personal use only Biotron’s approach enables the targeting of a wide range of viral diseases; examples include: • Hepatitis B virus (HBV) • Respiratory Viruses such as Respiratory Syncytial Virus (RSV), Influenza, & Coronaviruses (leading cause of “common
Slide 18: Hepatitis B Virus Program
Hepatitis B Virus Program For personal use only • Hepatitis B virus (HBV) therapeutic space has generated significant interest from pharma & biotech companies • Oct ‘18 – J&J and Arrowhead in deal worth up to US$3.7 billion • Screening of Biotron’s compound library has identified several compounds w
Slide 19: Commercialisation – Key Focus
Commercialisation – Key Focus For personal use only • Three tactical priorities: • Partnering lead clinical program ‐ BIT225 for HIV‐1 eradication • Partnering one or more preclinical programs – e.g. HBV • Execute a regional licensing deal in China ‐ HCV program remains a key potential opportunity
Slide 20: Commercialisation & Outlook for 2018/2019
Commercialisation & Outlook for 2018/2019 Commercialisation & Outlook for 2019 FY For personal use only • Aim is to achieve commercial outcomes for the company’s programs • Prime focus is partnering the HIV‐1 program • Data from the Phase 2 HIV‐1 trial to be presented at key conference(s), and also
Slide 21: Summary
Summary For personal use only • HIV‐1/BIT225 • BIT225‐009 Phase 2 trial provides clear clinical evidence that BIT225 is having a unique effect in individuals infected with HIV‐1 • Engaged with the right potential partners, with the right legal/commercial deal‐making skills in place • This is not a f
Slide 22: Thanks
Thanks For personal use only ‐ Huge thank you to Biotron’s small, focused, and highly dedicated team ‐ Thank you to Biotron’s contractors and consultants ‐ Thank you to shareholders, especially long‐term shareholders and those that participated in the recent rights issue